Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.59 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | GLI1 | P08151 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16584230 | 1.00 | SLC6A1 (0.59) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL6791489 | 1.00 | SLC6A1 (0.59) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16584210 | 0.98 | SLC6A1 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16584212 | 0.98 | SLC6A1 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6195102 | 0.98 | SLC6A1 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL31739419 | 0.94 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL5908361 | 0.88 | SLC6A1 (0.51) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2148728 | 0.88 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2146012 | 0.88 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2672481 | 0.88 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013755-B1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-01-08 | — | — | EP | claimed |
| CN-111386261-B | Coumarin derivatives, process for their preparation and their use in the treatment of cancer | 利德发现中心有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-115819328-A | Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases | 沈阳药科大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115557929-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | claimed |
| CN-114650995-A | [1,4] oxazepine [2,3-C ] quinolinone derivatives as BCL6 inhibitors | 癌症研究技术有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-109715617-B | Dimethoxyphenyl-substituted indole compounds as inhibitors of TLR7, TLR8 or TLR9 | 百时美施贵宝公司 | 2022-04-19 | — | — | CN | claimed |
| CN-113185451-A | Memantine urea derivative and preparation method and application thereof | 沈阳药科大学 | 2021-07-30 | — | — | CN | claimed |
| CN-111386261-A | Coumarin derivatives, preparation method thereof and application thereof in cancer treatment | 利德发现中心有限责任公司 | 2020-07-07 | — | — | CN | claimed |
| EP-2920183-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-23 | — | — | EP | claimed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | claimed |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| EP-4380928-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-1341762-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002068391-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5776720-A | COMPOUND OR SALT FOR ASSAYING ACTIVITY OF AN ENZYME INSIDE A METABOLICALLY ACTIVE WHOLE CELL | COULTER CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5147882-A | Cardiovascular disorders | KARL THOMAE GMBH (DE) | 1992-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | SLC6A1 3532/4885SLC6A11 3988/4885TSHR 4077/4885 |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | CYP1B1, CYP1A1, PAH | SLC6A1 792/4885SLC6A11 1679/4885TSHR 3378/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | SLC6A1 3395/4885SLC6A11 3458/4885TSHR 4665/4885 |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | KAT2B, KAT2A, KAT6A | SLC6A1 888/4885SLC6A11 1246/4885TSHR 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.